Evidence map›Paper›PMID 32542071›Full record

ArticleExpert review of ophthalmology2019

Ocular complications in Ebola virus disease survivors: the importance of continuing care in West Africa.

Duncan E Berry, Alexa L Li, Steven Yeh, Jessica G Shantha

Abstract read
In one paragraph

Article in Expert review of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Duncan E BerryDepartment of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Alexa L LiDepartment of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Steven YehDepartment of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Jessica G ShanthaDepartment of Ophthalmology, Emory Eye Center, Emory University School of Medicine, Atlanta, Georgia, USA.

Funding

P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI PARDUE, MACHELLE T. · 1986 to 2025
$15.3M
Neuro HPA Project 1U54AG062334 · NIA · EMORY UNIVERSITY · PI Ighovwerha Ofotokun · 2018 to 2026
$12.2M
Emory University BIRCWH ProgramK12HD085850 · NICHD · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, STERK, CLAIRE E · 2015 to 2023
$4.4M
Pathogenesis of Uveitis in Ebola Virus Disease SurvivorsR01EY029594 · NEI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI YEH, STEVEN · 2019 to 2023
$2.9M
Emory R38 Research Training ProgramR38AI140299 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, ROUPHAEL, NADINE GEORGES · 2018 to 2021
$1.4M
Ophthalmic Disease and Laboratory Surveillance in a Viral Hemorrhagic Fever ZoneK23EY030158 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANTHA, JESSICA · 2019 to 2023
$1.2M
NEI NIH HHS K23 EY030158NEI NIH HHS P30 EY006360NEI NIH HHS R01 EY029594NIAID NIH HHS R38 AI140299NIA NIH HHS U54 AG062334NICHD NIH HHS K12 HD085850
6 · The paper itself

Abstract

introductionThe largest Ebola virus (EBOV) outbreak occurred from 2013 - 2016 in West Africa and consequently resulted in the largest cohort of Ebola virus disease (EVD) survivors to date. Ocular disease is among the most common sequelae reported in EVD survivors. This review discusses the prevalence, manifestations, pathogenesis, diagnosis and management of EVD-related ocular disease. AREAS COVERED: An extensive review of the literature was performed to detail the prevalence and manifestations of EVD-related ocular disease. We also review current eye screening and treatment strategies and our current understanding and approach to invasive ophthalmic procedures including surgery. EXPERT OPINION: The ocular sequelae of EVD can lead to vision impairment or blindness, if untreated. Keys to the prevention of such an outcome include timely evaluation and access to appropriate ophthalmic care. The persistence of EBOV in the eye and other immune-privileged sites is the subject of ongoing investigation, but should not be a barrier to care if appropriate screening and biosafety measures are taken. Improved understanding of the pathogenesis of this condition and ongoing clinical care are needed for EVD survivors at-risk for ocular complications.

Indexed as

EbolaEbola sequalaeEbola virusEbola virus diseaseuveitis

Identifiers

PMID32542071
PMCPMC7295120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.